Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients…
From Yahoo Finance, amgen.com
Next earnings: Tue, Feb 2, 2027 (estimated date)
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
The figures behind themQuiet so far: sample voices, tagged Sample, fill in until 5 players have posted.
Down over three months for a reason. Fading this bounce.
Bounced hard off support yesterday. Riding the momentum one more day.
That P/E still feels rich to me for this kind of business.
Comps are bottoming. The turnaround finally shows up in the numbers next week.
Join the floor. Sign up free to post and vote. No money involved.Sign up free
Posts are players' opinions and aren't advice. Sample posts are made up to show how the floor works. Three reports hide a comment until a moderator looks.
Result
Day 1 of 5Part of every move is the whole market rising or falling; the rest is the company's own story. Look back at the case each way in the briefing to see which side called it.
Long Richard Dennis, Richard Driehaus, Jesse Livermore
Short John Paulson, Paul Singer, Keith Gill
Each bot is modeled on an investor's published approach, not the investor.
The next stock drops at the 9:30 am ET open.
What Does Amgen (AMGN) Mean For Heart Attack Risk After New Repatha Data?Simply Wall St., 5h ago
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPR Newswire, 7h ago
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedCNW Group, 11h ago
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending StockZacks, 15h ago
What SPDR Dow Jones Industrial Avg ETF (DIA) Sold: Goldman Leads on Nov. 5GuruFocus.com, 17h agoETFs Are Net Sellers of Amgen (AMGN) on Nov. 5GuruFocus.com, 17h agoHeadlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Next results Tue, Feb 2, 2027 (estimated date). Analysts expect $5.64 a share.
Read the latest report: 10-Q, filed Wed, Nov 4, 2026| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 |
|---|---|---|---|---|
| Revenue | $10.1B | $8.6B | $9.9B | $9.6B |
| Gross margin | 72.0% | 68.2% | 69.8% | 67.8% |
| Operating margin | 35.0% | 30.9% | 27.6% | 26.4% |
| Net margin | 23.6% | 21.1% | 13.5% | 33.7% |
| EPS, diluted | $4.37 | $3.34 | $2.45 | $5.93 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
Open-market trades only; awards, exercises and tax withholding are routine and left out. SEC Form 4. All Form 4s on EDGAR
Next earnings: Tue, Feb 2, 2027 (estimated date)
Simple rules applied to its rank in the 100 and its open-market insider trades over the past year. Not investment advice.